To access the MOC assessment, please login and press the green "Take course" button at the bottom of this page.

Objectives
As a result of this activity, participants will be able to:

  • Discuss the diagnostic approach to C3 Glomerulopathy, including consideration of biomarkers of disease.
  • Recall the current therapeutic approach to C3 Glomerulopathy and briefly discuss the advent of more targeted approaches.

Practice Change
As a result of this activity, participants will be able to:

  • More easily make the diagnosis of C3 Glomerulopathy and be able to select the optimal treatment approach for each patient.

PDF icon To view additional information on the Nemours Children's disclosure policy, right click on this link to open in a new window.

Session date: 
03/27/2024 - 8:00am to 9:00am EDT
Add to calendar: 
  • 1.00 MOC ABP - Pediatrics
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Please login or register to take this course.
Faculty List: 
Peer reviewer(s)

Carlos Araya, MD

has no relevant financial relationships to disclose at this time.
Speaker(s)

Carla Nester, MD, MSA, FASN

has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Biocryst;.
has a financial relationship (Grant Or Contract) with Achillion;.
has a financial relationship (Grant Or Contract) with Kira;.
has a financial relationship (Professional Services) with Silence Therapeutics;.
has a financial relationship (Grant Or Contract) with Apellis;.
has a financial relationship (Grant Or Contract) with Retrophin;.